A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model

Trial Profile

A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Respiratory tract infections; Rhinovirus infections
  • Focus Therapeutic Use
  • Sponsors Biota Holdings
  • Most Recent Events

    • 24 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top